Promising combo aims to shrink esophageal tumors before surgery
NCT ID NCT05659251
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can help people with a certain type of esophageal cancer. The goal is to shrink tumors more effectively and lower the chance of cancer coming back. About 48 adults with stage II to IVA esophageal squamous cell carcinoma will receive the combination treatment before their planned surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?